News and events

  • All
  • Events
  • Press release
  • Publication
Press release

ExeVir Announces First Patient Enrolled in Phase 1b/2 Clinical Study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19 (EN/FR/NL)

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first patient has been treated in a Phase 1b/2 global clinical study of XVR011, its potent COVID-19 neutralizing antibody.

Read More
Press release

ExeVir announces first subjects dosed Phase 1 clinical study of potent COVID-19 neutralizing antibody (EN/FR/NL)

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first subjects have been dosed in a Phase I clinical study of XVR011, its llama-derived antibody for the treatment and prevention of COVID-19.

Read More
Events

8th Annual HealthTech Investment Forum — 5-6 October 2021

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that it has closed its Series A financing raising a total of EUR 42 million / US$50 million.

Read More
Events

Bio Europe — 25-27 October 2021

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that it has closed its Series A financing raising a total of EUR 42 million / US$50 million.

Read More
Events

Knowledge for Growth — 27-29 September 2021

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that it has closed its Series A financing raising a total of EUR 42 million / US$50 million.

Read More